N. Ferrara, H. P. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nat Med, vol.9, issue.6, p.12778165, 2003.

W. Zhang, Z. Shen, H. Luo, X. Hu, L. Zheng et al., The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer, Curr Drug Targets, vol.18, issue.10, p.27138763, 2017.

S. Riondino, G. D. Monte, F. Fratangeli, F. Guadagni, M. Roselli et al., Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer, Cardiovasc Hematol Agents Med Chem, 2017.

H. Berrahmoune, B. Herbeth, J. V. Lamont, C. Masson, and P. S. Fitzgerald, Visvikis-Siest S. Heritability for plasma VEGF concentration in the Stanislas family study, Ann Hum Genet, vol.71, p.17227476, 2007.

S. Debette, S. Visvikis-siest, M. H. Chen, N. C. Ndiaye, C. Song et al., Identification of cis-and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels, Circ Res, vol.109, issue.5, p.21757650, 2011.

S. H. Choi, D. Ruggiero, R. Sorice, C. Song, T. Nutile et al., Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies, PLoS Genet, vol.12, issue.2, p.26910538, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01708531

P. Vempati, A. S. Popel, M. Gabhann, and F. , Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning, Cytokine Growth Factor Rev, vol.25, issue.1, p.24332926, 2014.

S. J. Harper and D. O. Bates, VEGF-A splicing: the key to anti-angiogenic therapeutics?, Nature reviews Cancer, vol.8, issue.11, p.18923433, 2008.

J. Woolard, H. S. Bevan, S. J. Harper, and D. O. Bates, Molecular diversity of VEGF-A as a regulator of its biological activity, Microcirculation, vol.16, issue.7, p.19521900, 2009.

D. G. Nowak, E. M. Amin, E. S. Rennel, C. Hoareau-aveilla, M. Gammons et al., Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis, J Biol Chem, vol.285, issue.8, pp.5532-5572, 2010.

S. J. Harper and D. O. Bates, VEGF-A splicing: the key to anti-angiogenic therapeutics?, Nat Rev Cancer, vol.8, issue.11, p.18923433, 2008.

F. Mor, F. J. Quintana, and I. R. Cohen, Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization, J Immunol, vol.172, issue.7, p.15034080, 2004.

M. W. Kieran, R. Kalluri, and Y. J. Cho, The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward. Cold Spring Harb Perspect Med, vol.2, 2012.

C. P. Corkum, D. P. Ings, C. Burgess, S. Karwowska, W. Kroll et al., Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT()) and standard density gradient, BMC Immunol, vol.16, 2015.

J. M. Lackie, The Dictionary of Cell and Molecular Biology, 2012.

A. Miyahira, PBMC Basic: Sanguine Biosciences, 2012.

L. S. Angelo and R. Kurzrock, Vascular endothelial growth factor and its relationship to inflammatory mediators, Clin Cancer Res, vol.13, issue.10, p.17504979, 2007.

M. D. Turner, B. Nedjai, T. Hurst, and D. J. Pennington, Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease, Biochim Biophys Acta, vol.1843, issue.11, p.24892271, 2014.

W. E. Paul and R. A. Seder, Lymphocyte responses and cytokines, Cell, vol.76, issue.2, pp.241-51, 1994.

C. F. Krieglstein and D. N. Granger, Adhesion molecules and their role in vascular disease, Am J Hypertens, vol.14, issue.6, p.11411765, 2001.

P. Salven, K. Hattori, B. Heissig, and S. Rafii, Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion, FASEB J, vol.16, issue.11, p.12205052, 2002.

P. Repovic, C. Y. Fears, C. L. Gladson, and E. N. Benveniste, Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells, Oncogene, vol.22, issue.50, p.14603252, 2003.

D. Palma and M. , Partners in crime: VEGF and IL-4 conscript tumour-promoting macrophages, J Pathol, vol.227, issue.1, p.22367978, 2012.

K. Hong, M. Cho, M. S. Shin, Y. Yoo, S. Choi et al., Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts, Clin Exp Immunol, vol.147, issue.3, p.17302909, 2007.

D. S. Faffe, L. Flynt, K. Bourgeois, R. A. Panettieri, and S. A. Shore, Interleukin-13 and Interleukin-4 Induce Vascular Endothelial Growth Factor Release from Airway Smooth Muscle Cells: Role of Vascular Endothelial Growth Factor Genotype, Am J Respir Cell Mol Biol, vol.34, issue.2, p.16210693, 2006.

S. P. Huang, M. S. Wu, C. T. Shun, H. P. Wang, M. T. Lin et al., Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma, J Biomed Sci, vol.11, issue.4, p.15153787, 2004.

K. Saito, H. Nakaoka, I. Takasaki, K. Hirono, S. Yamamoto et al., MicroRNA-93 may control vascular endothelial growth factor A in circulating peripheral blood mononuclear cells in acute Kawasaki disease, Pediatr Res, vol.80, issue.3, p.27089500, 2016.

M. Hoekstra, C. A. Van-der-lans, B. Halvorsen, L. Gullestad, J. Kuiper et al., The peripheral blood mononuclear cell microRNA signature of coronary artery disease, Biochem Biophys Res Commun, vol.394, issue.3, p.20230787, 2010.

H. Aziz, A. Zaas, and G. S. Ginsburg, Peripheral blood gene expression profiling for cardiovascular disease assessment, Genomic Med, vol.1, issue.3, pp.105-117, 2007.

V. O. Shah, R. I. Dorin, Y. Sun, M. Braun, and P. G. Zager, Aldose Reductase Gene Expression Is Increased in Diabetic Nephropathy1, The Journal of Clinical Endocrinology & Metabolism, vol.82, issue.7, pp.2294-2302, 1997.

E. G. Giannopoulou, O. Elemento, and L. B. Ivashkiv, Use of RNA sequencing to evaluate rheumatic disease patients, Arthritis Res Ther, vol.17, issue.1, p.167, 2015.

I. Nikolayeva, P. Bost, I. Casademont, V. Duong, F. Koeth et al., A Blood RNA Signature Detecting Severe Disease in Young Dengue Patients at Hospital Arrival, J Infect Dis, 2018.
URL : https://hal.archives-ouvertes.fr/pasteur-02088893

R. R. Erusan, D. Nalini, G. Manohar, and R. Malathi, Correlation between obesity and inflammation in cardiovascular diseases-evaluation of leptin and inflammatory cytokines, Open Journal of Endocrine and Metabolic Diseases, vol.2, issue.02, p.7, 2012.

H. Nakagomi, P. Pisa, E. K. Pisa, Y. Yamamoto, E. Halapi et al., Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma, Int J Cancer, vol.63, issue.3, p.7591233, 1995.

G. S. Hotamisligil, Inflammation and metabolic disorders, Nature, vol.444, issue.7121, p.17167474, 2006.

K. H. Hong, M. L. Cho, S. Y. Min, Y. J. Shin, S. A. Yoo et al., Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts, Clin Exp Immunol, vol.147, issue.3, p.17302909, 2007.

P. H. Hart, G. F. Vitti, D. R. Burgess, G. A. Whitty, D. S. Piccoli et al., Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2, Proc Natl Acad Sci U S A, vol.86, issue.10, p.2786204, 1989.

N. Linde, W. Lederle, S. Depner, N. Van-rooijen, C. M. Gutschalk et al., Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages, J Pathol, vol.227, issue.1, p.22262122, 2012.

T. Skaria, J. Burgener, E. Bachli, and G. Schoedon, IL-4 Causes Hyperpermeability of Vascular Endothelial Cells through Wnt5A Signaling, PLoS One, vol.11, issue.5, 2016.

S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, Monocyte Chemoattractant Protein-1 (MCP-1): An Overview, J Interferon Cytokine Res, vol.29, issue.6, p.19441883, 2009.

K. H. Hong, J. Ryu, and K. H. Han, Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A, Blood, vol.105, issue.4, p.15498848, 2005.

T. Ueno, M. Toi, H. Saji, M. Muta, H. Bando et al., Significance of Macrophage Chemoattractant Protein-1 in Macrophage Recruitment, Angiogenesis, and Survival in Human Breast Cancer. Clin Cancer Res, vol.6, issue.8, p.10955814, 2000.

A. Parenti, L. Bellik, L. Brogelli, S. Filippi, and F. Ledda, Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells, American Journal of Physiology-Heart and Circulatory Physiology, vol.286, issue.5, p.14693680, 2004.

S. M. Jay, B. R. Shepherd, J. W. Andrejecsk, T. R. Kyriakides, J. S. Pober et al., Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization, Biomaterials, vol.31, issue.11, p.20110124, 2010.

T. Cohen, D. Nahari, L. W. Cerem, G. Neufeld, and B. Z. Levi, Interleukin 6 induces the expression of vascular endothelial growth factor, J Biol Chem, vol.271, issue.2, p.8557680, 1996.

L. H. Wei, M. L. Kuo, C. A. Chen, C. H. Chou, K. B. Lai et al., Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway, Oncogene, vol.22, issue.10, p.12629515, 2003.

Y. Adachi, C. Aoki, N. Yoshio-hoshino, K. Takayama, D. T. Curiel et al., Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas, Int J Cancer, vol.119, issue.6, p.16642474, 2006.

Z. Dembic, The Cytokines of the Immune System: The Role of Cytokines in Disease Related to Immune Response, 2015.

C. A. Dinarello, Biologic basis for interleukin-1 in disease, Blood, vol.87, issue.6, p.8630372, 1996.

R. F. Tang, S. X. Wang, F. R. Zhang, L. Peng, S. X. Wang et al., Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer, Hepatobiliary Pancreat Dis Int, vol.4, issue.3, p.16109537, 2005.

S. A. Borg, K. E. Kerry, J. A. Royds, R. D. Battersby, and T. H. Jones, Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells, Eur J Endocrinol, vol.152, issue.2, p.15745939, 2005.

G. Carpenter and S. Cohen, Epidermal growth factor, J Biol Chem, vol.265, issue.14, p.2186024, 1990.

L. Saryeddine, K. Zibara, N. Kassem, B. Badran, and N. El-zein, EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models, PLoS One, vol.11, issue.11, p.27806094, 2016.

E. Witsch, M. Sela, and Y. Yarden, Roles for growth factors in cancer progression, Physiology (Bethesda), vol.25, issue.2, pp.85-101, 2010.

A. Citri and Y. Yarden, EGF-ERBB signalling: towards the systems level, Nature Reviews Molecular Cell Biology, vol.7, p.16829981, 2006.

F. Ciardiello, T. Troiani, R. Bianco, M. Orditura, F. Morgillo et al., Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy, Ann Oncol, vol.17, issue.7, pp.109-123, 2006.

G. Tortora, F. Ciardiello, and G. Gasparini, Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications, Nat Clin Pract Oncol, vol.5, issue.9, p.18594498, 2008.

J. Tabernero, The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents, Mol Cancer Res, vol.5, issue.3, p.17374728, 2007.

T. Winder and H. J. Lenz, Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer, Gastroenterology, vol.138, issue.6, p.20420953, 2010.

Y. Cao, W. R. Ji, P. Qi, A. Rosin, and Y. Cao, Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing, Biochem Biophys Res Commun, vol.235, issue.3, p.9207183, 1997.

R. Cressey, O. Wattananupong, N. Lertprasertsuke, and U. Vinitketkumnuen, Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis, BMC Cancer, vol.5, p.16202150, 2005.

M. Canavese, D. T. Ngo, G. J. Maddern, J. E. Hardingham, T. J. Price et al., Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer, Int J Cancer, vol.140, issue.10, p.27943279, 2017.

R. Kikuchi, An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease, vol.20, pp.1464-71, 2014.

M. Stevens and S. Oltean, Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease, Genes (Basel), vol.9, issue.2, 2018.

M. Manetti, S. Guiducci, E. Romano, C. Ceccarelli, S. Bellando-randone et al., Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis, Circ Res, vol.109, issue.3, p.21636803, 2011.

S. L. Barratt, T. Blythe, C. Jarrett, K. Ourradi, G. Shelley-fraser et al., Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis, Am J Respir Crit Care Med, vol.196, issue.4, p.28661183, 2017.

D. O. Bates, T. G. Cui, J. M. Doughty, M. Winkler, M. Sugiono et al., VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma, Cancer Res, vol.62, issue.14, p.12124351, 2002.

J. Bunni, G. Shelley-fraser, K. Stevenson, S. Oltean, A. Salmon et al., Circulating levels of antiangiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios, Am J Cancer Res, vol.5, issue.6, p.26269767, 2015.

A. H. Varey, E. S. Rennel, Y. Qiu, H. S. Bevan, R. M. Perrin et al., VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy, Br J Cancer, vol.98, issue.8, p.18349829, 2008.

K. S. Jeng, I. S. Sheen, Y. C. Wang, S. L. Gu, C. M. Chu et al., Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?, World J Gastroenterol, vol.10, issue.5, p.14991937, 2004.

B. Paule, L. Bastien, E. Deslandes, O. Cussenot, M. P. Podgorniak et al., Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas, PLoS One, vol.5, issue.5, p.20502715, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00490677

L. E. Clegg, M. Gabhann, and F. , A computational analysis of pro-angiogenic therapies for peripheral artery disease, Integr Biol (Camb), vol.10, issue.1, pp.18-33, 2018.

M. Guyot, C. Hilmi, D. Ambrosetti, M. Merlano, L. Nigro et al., Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies, Oncotarget, vol.8, issue.6, p.27999187, 2017.